FindTrial
Sign In

A long-term extension study of AG-1749 in patients on concomitant long-term low-dose aspirin therapy

A long-term extension study of AG-1749 in patients on concomitant long-term low-dose aspirin therapy

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220830
Enrollment
Unknown
Registered
2009-08-26
Start date
2009-08-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of onset of low dose aspirin related gastric ulcer

Interventions

investigational material(s) Generic name etc : AG-1749 INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who have finished the preceding confirmatory anti-ulcer efficacy study 2. Patients who are on oral low-dose aspirin at the time of consent and who require continued long-term use of low-dose aspirin even after the start of study treatment in this study

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026